Treatment with homoharringtonine and cytarabine in patients with high risk acute myelogenous leukemia (AML).

被引：0
|
作者：
Chang, Naibai [1 ]
Wei, Jianping [1 ]
Zhao, Shengming [1 ]
Liu, Hui [1 ]
Fan, Yun [1 ]
Li, Jiangtao [1 ]
Xu, Xiaodong [1 ]
Gu, Xichun [1 ]
机构：
[1] Beijing Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4555
引用
收藏
页码：218B / 218B
页数：1
相关论文
共 50 条
  • [1] HOMOHARRINGTONINE IN COMBINATION WITH CYTARABINE FOR PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA
    FELDMAN, E
    ARLIN, Z
    AHMED, T
    MITTELMAN, A
    PUCCIO, C
    CHUN, H
    COOK, P
    BASKIND, P
    LEUKEMIA, 1992, 6 (11) : 1189 - 1191
  • [2] Homoharringtonine, cytarabine and cyclopbosphamide in patients with acute myelogenous leukemia for induction chemotherapy
    Qiao, ZH
    Su, LP
    Jia, HF
    Liu, GJ
    Pei, YH
    BLOOD, 2002, 100 (11) : 259B - 259B
  • [3] HOMOHARRINGTONINE IS SAFE AND EFFECTIVE FOR PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA
    FELDMAN, E
    ARLIN, Z
    AHMED, T
    MITTELMAN, A
    PUCCIO, C
    CHUN, H
    COOK, P
    BASKIND, P
    LEUKEMIA, 1992, 6 (11) : 1185 - 1188
  • [4] Homoharringtonine in childhood acute myelogenous leukemia
    Tang, JY
    Xue, HL
    Pan, C
    Chen, J
    Gu, LJ
    Chen, J
    Zhao, HJ
    Wang, YP
    BLOOD, 2002, 100 (11) : 260B - 260B
  • [5] INFECTION OF ELDERLY PATIENTS RECEIVING HIGH-DOSE CYTARABINE-BASED CHEMOTHERAPY FOR INDUCTION TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA (AML)
    NEMUNAITIS, J
    MEYER, W
    NEMUNAITIS, J
    TAYLOR, E
    RILEY, C
    COOPER, B
    LEUKEMIA RESEARCH, 1994, 18 (08) : 649 - 650
  • [6] Achievements in the treatment of acute myelogenous leukemia (AML)
    Zittoun, R
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 617 - 617
  • [7] Homoharringtonine for the treatment of chronic myelogenous leukemia
    Quintas-Cardama, Alfonso
    Cortes, Jorge
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (06) : 1029 - 1037
  • [8] Priming GM-CSF and low dose cytarabine (LODAC) in the treatment of high risk and elderly acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) patients.
    Winer, ES
    Miller, KB
    Chan, GW
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 585S - 585S
  • [9] HIGH-DOSE CYTARABINE IN ACUTE MYELOGENOUS LEUKEMIA
    ZITTOUN, R
    BONE MARROW TRANSPLANTATION, 1989, 4 : 38 - 42
  • [10] Azatidine Treatment in Very Elderly Patients Diagnosed with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
    Gutierrez, Javier
    Morales, Elena
    Gonzalez, Matilde
    Herrada, Juan
    BLOOD, 2015, 126 (23)
12345